

Index

- Abbott, Andrew, 31
- Advertisements, 32–34, 82, 83, 84, 88, 89, 127, 128, 129, 130, 153, 154
- Advisory Committee on Genetic Testing, 51–53, 75, 93
- Akrich, Madeline, 20
- American Cancer Society, 3
- American College of Obstetrics and Gynecology, 65–68, 75, 119
- American Medical Association, 31, 65, 119–122, 150
- American Society of Clinical Oncology, 65–68, 90, 92, 120
- American Society of Human Genetics, 28, 35, 65–68, 75, 79, 88, 93, 120, 122, 179
- Amniocentesis, 19, 29, 47
- Annan, Kofi, 2
- “A Policy Framework for Commissioning Cancer Services,” 104, 105
- Architecture, 18–21, 93–95, 111–115, 142, 145, 146, 196, 197, 202, 203, 210, 211
- Ashkenazi Jews, 79–86, 90, 115, 131, 149, 200, 218
- Assessing Genetic Risks*, 37–42, 52, 53, 209
- AstraZeneca. *See* Zeneca
- Bayh-Dole Act (1980), 188
- Baylor College of Medicine, 31
- Bevan, Aneurán, 45
- Bijker, Wiebe, 13, 14
- Biotech Patent Directive. *See* EU Directive
- Birth-control pill, 63
- Blair, Tony, 45
- Blood-pressure testing, 19
- Boundary object, 70
- Boundary work, 64
- Breast Cancer Action, 4, 58–64, 67, 99, 119, 126
- Breast cancer genes
- BRCA1 (BRCA1), 9, 19, 61, 62, 65, 70, 74, 86, 87, 90, 116, 148, 150, 166, 168, 178, 186, 187, 209, 215
- BRCA2 (BRCA2), 19, 61, 70, 74, 87, 90, 116, 148, 150, 166, 168, 178, 186, 209, 218
- discovery of, 5, 6, 9
- mechanisms of disease causation, 6
- penetrance, 6, 120, 125, 148, 149, 162
- Breast Cancer Prevention Trial, 155–158, 163, 165
- Brickman, Ronald, 11
- British Association of Surgical Oncology, 164
- British Society of Human Genetics, 102, 178, 182–185
- Brokaw, Tom, 5

- CA-125 screening, 153
 Callon, Michel, 119
 Calman-Hine Report, 104, 105
 Calman, Kenneth, 105
 Cancer Research Campaign, 3, 74, 213
 Celera Genomics, 73
 Center for Medicare and Medicaid Services, 35
 Centers for Disease Control and Prevention, 35, 206
 Church of Scotland, 183
 Client, 20, 21
 as citizen and patient, 111, 114
 empowerment of, 63–68, 91, 127–133
 as individual and consumer, 113, 124, 132, 133, 143, 159, 190, 191, 201, 203, 205–207
 as member of ethnic group, 85, 86
 as member of family, 68
 Client demand, 171–173
 Clinical Laboratories Improvement Act Advisory Committee, 39, 41, 44
 Clinical Laboratories Improvement Acts (1967, 1988), 35–37, 41–44, 67
 Clinical Molecular Genetics Society, 101, 102, 178, 184, 189–192
 Clinton, William J., 1, 2
 College of American Pathologists, 36
 Collins, Francis, 80
 Comparative analysis, 10–12, 27, 57, 58, 138, 139, 209–212
 Conformation Sensitive Gel Electrophoresis, 69, 71, 93, 101
 Continuing Medical Education module. *See* Myriad
 Council of Regional Genetic Networks of Genetic Services, 36
 Coventry, Peter, 47
 Cystic fibrosis, 31, 52, 205

 Danish Patients with Genetic Disorders, 182
 De Laet, Marianne, 180

 Department of Defense, 4
 Department of Health and Human Services, 44
 Department of Health, 52, 97, 105, 178, 193, 196
 Department of Trade and Industry, 52
Diamond v. Chakrabarty, 179
 Diethylstilbestrol, 63
 DNA Direct, 204, 205
 Down's Syndrome, 29, 48
 Duster, Troy, 8

 Eli Lilly, 86, 87
 Endpoint Review, Safety Monitoring, and Advisory Committee, 156
 Epstein, Steve, 62, 63
 EU Directive for the Legal Protection of Biotechnological Inventions, 181–184
 Eugenics, 8, 28, 36, 208
 European Familial Breast Cancer Demonstration Project, 176
 European Parliament, 181–183
 European Patent Convention, 180, 181
 European Patent Office, 176, 180, 181, 213–218
 European Union, 181–183
 Evans, Gareth, 137
 Expert Advisory Group on Cancer, 105
 Expertise, 37, 40, 52, 62, 63, 97, 99, 135, 136, 139–141

 Familial breast cancer, 150, 151, 160–162
 Food and Drug Administration, 24, 37–44, 55, 62, 63, 78, 93, 119, 167
 Friedan, Betty, 4

 GenBank, 186
 Genetic Diagnostic Laboratory, University of Pennsylvania, 68–72, 77–81, 85, 90–95, 115, 125, 177, 200
 Genetic essentialism, 7–10

- Genetic exceptionalism, 7–10
- Genetic counseling, 28, 29, 36–39, 42–47, 59–62, 66–68, 78, 79, 92
- Genetic Interest Group, 97–99, 105, 135, 136, 139–141
- Geneticization, 7–10
- Genetics and Cancer Services report, 104–108
- Genetics and IVF Institute, 31, 79–86, 91–95, 98, 100, 107, 110, 114, 115, 177, 200
- Genetic testing, 5–9, 17, 18, 27–52, 60, 82, 101, 153–159, 166
- Genomics and Global Health Program of UN Millennium Development Project, 2
- Genzyme Genetics, 31
- Gieryn, Thomas, 64
- Greenpeace, 182, 214, 217
- Griesemer, James, 70
- Hadassah, 81
- Haites, Neva, 177, 192
- Harper Committee Report, 104–108
- Health Care Financing Administration, 35
- Health insurance, 27, 82, 129, 131, 218
- Health outcomes, 170–173
- Hereditary breast cancer, 150, 158, 162
- Hereditary Cancer Risk Assessment Service, 73
- Hilgartner, Stephen, 37
- Hine, Dierdre, 104
- House of Commons Science and Technology Committee, 51
- “Human Genetics: The Science and Its Consequences,” 51
- Hubbard, Ruth, 80
- Hughes, Thomas, 14
- Human Genetics Advisory Commission, 51, 52, 206
- Human Genome Project, 7, 16, 73, 179
- Icelandic genome database, 2
- Imperial Cancer Research Fund, 3
- Inherited cancer susceptibility, 150, 151, 162
- Institute Curie, 215–217
- Institute for Cancer Research, 5, 6
- Institute of Medicine Report, 37–42, 52, 53, 209
- Institutional Review Board, 75, 76
- International Breast Cancer Intervention Study, 164–166
- International Tay-Sachs Disease Quality Control Reference Standards and Data Collection Center, 36
- In vitro fertilization, 31, 92, 179
- Jasanoff, Sheila, 11, 12
- Karyotyping, 29, 47
- King, Mary-Claire, 5, 74, 86, 92
- Kushner, Rose, 4
- LabCorp, 120, 205
- Latour, Bruno, 126
- Lippman, Abby, 7
- Lock, Margaret, 148
- Lorde, Audre, 4
- Los Angeles Jewish Times*, 82, 83
- Mackay, James, 107–109, 133, 134, 138, 168, 169
- MacKenzie, Donald, 17
- Major, John, 51
- Mammography, 3, 108, 109, 137, 153, 163, 170
- Mastectomy
 prophylactic, 96, 108, 140, 153–155, 159, 169, 171
 therapeutic, 3, 4
- Matthijs, Gert, 218
- Mayo Clinic, 31
- Medichecks, 133
- Meldrum, Peter, 117

- Millennium Development Program. *See* Genomics and Global Health Program
- Moore, John, 179
- Moore v. Regents of University of California*, 179
- Murphy, Patricia, 75, 76
- Myriad Genetics, Inc., 86–95, 99–102, 107, 110, 113–135, 142, 143, 146–153, 158, 159, 173, 177, 178, 193–196, 204, 207, 209
- National Academy of Sciences, 37
- National Action Plan on Breast Cancer, 75
- National Alliance of Breast Cancer Organizations, 126, 127
- National Breast Cancer Coalition, 4, 58–67, 79, 88, 95, 119, 126
- National Cancer Institute, 3, 124, 125
- National Center for Human Genome Research, 37, 80
- National Health Service, 16, 18, 22–27, 31, 45–55, 58, 74, 96–114, 133–142, 159–161, 168–170, 177, 189, 191, 194, 202
- National innovation systems, 11
- National Institute of Clinical Excellence, 140–144, 162, 166, 170–172, 203–206
- National Institutes of Health, 5, 64
- NIH–Department of Energy Working Group on Ethical, Legal and Social Implications of Human Genome Research, 40
- National Insurance Act (1911), 45
- National Society of Genetic Counselors, 35
- National Surgical Adjuvant Breast and Bowel Project, 155, 165
- National Tay-Sachs and Allied Diseases Association, 36
- National Women’s Health Network, 156
- Nutrigenetic testing, 208
- Oncomouse, 180, 181
- Oncormed, Inc., 72–85, 90–97, 101, 113–117, 146, 177, 192
- Our Bodies, Ourselves*, 63
- Patenting of genes, 12, 25, 32, 51, 73, 74, 77, 87, 116–119, 126, 178–188, 193–197, 200, 201
- Patient advocacy, 4, 58–65, 72, 78, 88, 92, 96–99, 111–114, 126, 127, 132–136, 178, 179, 193
- Pharmacogenetic testing, 207
- Phenylketonuria, 29
- Pickstone, John, 47
- Ponder, Bruce, 135, 185
- President’s Cancer Panel, 4
- President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 29–31, 35, 42
- Protein truncation testing, 78, 101
- Public Health Genetics Unit, 133, 134, 138, 143, 161, 166, 168, 206
- Rabinow, Paul, 2
- Rapid BRACAnalysis. *See* Myriad Rosgen, 194–197
- Schulman, Joseph, 79–81
- Sciona, Inc., 208
- Secretary’s Advisory Committee on Genetic Testing, 44
- Sickle-cell anemia, 29, 31
- Skolnik, Mark, 126
- Sociology of technology, 12–14, 17
- Star, Susan Leigh, 70
- Starr, Paul, 31
- Stern, Harvey, 81
- Stoppa-Lyonnet, Dominique, 216

- Stratton, Mike, 74, 75, 186, 193, 194, 213, 215
- Swidler, Ann, 14, 15
- Tamoxifen, 24, 155–158, 164–168, 171, 204
- Task Force on Genetic Testing, 40–44, 53, 75, 209
- Technology assessment, 210, 211
- Thatcher, Margaret, 45
- Therapeutic gap, 9
- Toolkits, 14, 15, 27, 44, 49, 54, 57, 58, 196, 199, 211
- Triage and risk assessment, 49, 50, 104, 106, 133–136, 139, 143, 202, 203
- UK Cancer Family Study Group, 102, 104, 133, 143, 177, 203
- UK Cancer Research Campaign, 74
- UK Department of Health. *See* Department of Health
- UK Department of Trade and Industry. *See* Department of Trade and Industry
- UK Patent Office, 194
- UK Public Health Genetics Unit. *See* Public Health Genetics Unit
- University of Utah, 86
- US Patent and Trademark Office, 16, 116, 180
- US Preventive Services Task Force, 206
- Variants of uncertain significance, 151, 152
- Varmus, Harold, 5
- Venter, Craig, 73, 74, 179
- Vogel, David, 10
- Wailoo, Keith, 21
- Wajcman, Judy, 17
- Watson, James, 199
- Watson, Wendy, 96–99, 135, 136, 139–141, 178, 183, 187, 188, 193
- Woolgar, Steven, 20
- Zeneca Pharmaceuticals, 157, 166, 167, 204
- Zimmern, Ron, 107, 108, 110, 133, 138, 160

